Trial Profile
A Multicenter Randomized Dble-Blind Placebo Controlled Phase III Study of the Efficacy of Xaliproden in Reducing the Neurotoxicity of the Oxaliplatin and 5-FU/LV Combination in First-Line Treatment of Patients With Metastatic Colorectal Carcinoma(MCRC)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 27 Feb 2020
Price :
$35
*
At a glance
- Drugs Xaliproden (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- Acronyms XENOX
- Sponsors Sanofi
- 25 Jan 2020 Results assessing the patterns of opioid use, and evaluating the impact of opioid use on survival outcomes among patients with advanced GI cancers who were included in eight clinical trials (NCT01124786; NCT00844649; NCT00290966; NCT00678535; NCT00699374; NCT00272051; NCT00305188; NCT00384176) presented at the 2020 Gastrointestinal Cancers Symposium
- 09 Jun 2014 New trial record